International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(1), С. 781 - 781
Опубликована: Янв. 2, 2023
Atopic
dermatitis
is
a
chronic,
recurrent
inflammatory
skin
disorder
manifesting
by
eczematous
lesions
and
intense
pruritus.
develops
primarily
as
result
of
an
epidermal
barrier
defect
immunological
imbalance.
Advances
in
understanding
these
pathogenetic
hallmarks,
particularly
the
complex
role
interleukins
atopic
drivers,
resulted
achieving
significant
therapeutic
breakthroughs.
Novel
medications
involve
monoclonal
antibodies
specifically
blocking
function
selected
small
molecules
such
Janus
kinase
inhibitors
limiting
downstream
signaling
to
reduce
expression
wider
array
proinflammatory
factors.
Nevertheless,
subset
patients
remains
refractory
those
treatments,
highlighting
complexity
immunopathogenesis
different
populations.
In
this
review,
we
address
heterogeneity
endotypes
phenotypes
present
novel
interleukin-oriented
therapies
for
disease.
Aim
:
investigate
the
possible
anti-psoriatic
effect
of
ivermectin
in
mice
based
on
observational
and
histopathological
outcomes
biomarkers.
Methods
Sixty
male
Swiss
Albino
Mice
were
divided
into
six
groups
(Groups
I–VI);
each
group
contained
ten
with
shaved
dorsal
skin.
The
clinical,
pathological,
laboratory
effects
measured.
Results
Topical
Ivermectin
significantly
decreased
vascular
endothelial
growth
factor
levels.
At
same
time,
combination
plus
Clobetasol
showed
a
more
significant
reduction
tumor
necrosis
factor-alpha
(TNF-α)
Interleukin-17
(IL-17)
Regarding
Interleukin-10
(IL-10)
level,
Ivermectin/Clobetasol
increase
IL-10.
Conclusion
Ivermectin’s
anti-psoriasis
activity
increases
IL-10
levels
could
be
used
efficiently
to
alleviate
psoriatic
symptoms.
Its
treatment
holds
promise
for
management
psoriasis.
European Journal of Immunology,
Год журнала:
2024,
Номер
54(5)
Опубликована: Фев. 14, 2024
Abstract
Although
biologics
have
achieved
tremendous
success
in
the
treatment
of
psoriasis
and
revolutionized
clinical
management
disease,
certain
issues
arise
during
treatments,
including
phenotypic
switch
from
to
other
skin
disorders
recurrence
after
cessation
biologic
treatment.
Here
we
provide
a
concise
overview
roles
keratinocytes
pathogenesis
psoriasis,
elucidate
involvement
relapse
address
challenges
encountered
both
basic
research
on
psoriasis.
International Journal of Dermatology,
Год журнала:
2024,
Номер
63(10), С. 1392 - 1397
Опубликована: Март 3, 2024
Abstract
Background
Psoriasis
(Ps)
and
atopic
dermatitis
(AD)
are
chronic
systemic
immune‐mediated
diseases
that
can
coexist
in
an
overlapping
condition
called
psoriasis
(PD).
PD
patients
have
intermediate
lesions
with
characteristics
of
both
Ps
AD.
is
very
rare
adults
but
much
more
frequent
children.
Little
known,
however,
about
the
course
pediatric
population.
The
aim
this
study
was
to
evaluate
percentage
cases
children
evolved
a
definite
form
or
AD
identify
any
clinical
epidemiological
variables
could
predict
disease.
Methods
We
performed
prospective
multicenter
cohort
diagnosed
between
January
2018
December
2020.
collected
participants'
characteristics,
dermatologists
determined
participants
who
developed
Results
included
24
PD,
median
age
7.0
years.
After
follow‐up
period
31
months,
83.3%
had
(44.4%
38.9%
AD).
Younger
family
history
were
associated
progression
Participants
progressed
longer
than
those
unchanged
diagnosis.
Conclusions
Given
sufficient
time,
large
will
evolve
into
Long‐term
necessary
for
correct
Journal of Clinical Medicine,
Год журнала:
2022,
Номер
12(1), С. 328 - 328
Опубликована: Дек. 31, 2022
The
coexistence
of
psoriasis
with
autoimmune
bullous
diseases
(AIBDs),
particularly
pemphigoid
(BP),
has
been
documented
in
case
reports
and
series,
as
well
epidemiological
studies.
onset
precedes
that
BP
the
majority
cases.
Patients
concomitant
are
generally
younger
at
present
fewer
erosions
blisters
compared
patients
suffering
from
isolated
BP.
Intriguingly,
it
speculated
some
cases
comorbid
can
actually
correspond
to
anti-laminin
gamma-1
pemphigoid,
a
rare
form
was
recently
recognized
distinct
entity
which
mimic
and/or
other
subepidermal
AIBDs.
pathomechanisms
underlying
BP–psoriasis
association
have
not
yet
identified,
although
several
hypotheses
proposed.
most
credited
among
such
involves
so-called
“epitope
spreading”
phenomenon,
tissue
injury
secondary
primary
inflammatory
process
(i.e.,
psoriasis)
leading
exposure
sequestered
antigens
evoking
disease
pemphigoid).
This
narrative
review
aims
give
brief
overview
between
BP,
examining
epidemiological,
clinical,
immunopathological
features,
this
association,
treatments
for
incriminated
potential
triggers
therapeutic
management
Asian Journal of Pharmaceutical Sciences,
Год журнала:
2023,
Номер
18(5), С. 100846 - 100846
Опубликована: Сен. 1, 2023
Psoriasis
is
an
inflammatory
skin
disease
that
intricately
linked
to
oxidative
stress.
Antioxidation
and
inhibition
of
abnormal
proliferation
keratinocytes
are
pivotal
strategies
for
psoriasis.
Delivering
drugs
with
these
effects
the
site
lesions
a
challenge
needs
be
solved.
Herein,
we
reported
nanotransdermal
delivery
system
composed
all-trans
retinoic
acid
(TRA),
triphenylphosphine
(TPP)-modified
cerium
oxide
(CeO2)
nanoparticles,
flexible
nanoliposomes
gels
(TCeO2-TRA-FNL-Gel).
The
results
revealed
TCeO2
synthesized
by
anti-micelle
method,
size
approximately
5
nm,
possessed
excellent
mitochondrial
targeting
ability
valence
conversion
capability
related
scavenging
reactive
oxygen
species
(ROS).
TCeO2-TRA-FNL
prepared
film
dispersion
70
showed
high
drug
encapsulation
efficiency
(>96%).
TCeO2-TRA-FNL-Gel
further
sustained
release
behaviors,
great
transdermal
permeation
ability,
greater
retention
than
free
TRA.
in
vitro
EGF-induced
H2O2-induced
models
suggested
effectively
reduced
level
inflammation
alleviated
stress
HaCat
cells.
vivo
imiquimod
(IMQ)-induced
model
indicated
could
greatly
alleviate
psoriasis
symptoms.
In
summary,
designed
this
study
has
shown
therapeutic
on
prospective
safe
accurate
therapy
Journal of Dermatological Treatment,
Год журнала:
2023,
Номер
34(1)
Опубликована: Сен. 13, 2023
Purpose:
Although
psoriasis
and
atopic
dermatitis
(AD)
were
for
decades
considered
to
be
opposing
diseases,
it
is
now
known
that
these
skin
conditions
can
coexist
or
even
overlap
in
the
same
individual.
Especially
when
using
modern
drugs
with
targeted
IL
inhibition,
balance
between
Th1
Th2
immunity
disturbed.
In
line
it,
numerous
clinical
cases
of
AD
have
been
induced
by
antipsoriatic
biologics
(e.g.,
TNF-alpha,
IL-23,
IL-17
inhibitors),
IL-4-/IL-13
inhibition
dupilumab
also
resulted
paradoxical
patients
AD.
